继发性甲状旁腺功能亢进消融治疗进展

Progress of ablation for secondary hyperparathyroidism

继发性甲状旁腺功能亢进（SHPT）是透析患者的常见并发症，与患者生活质量、心血管事件和死亡密切相关。活性维生素D及其类似物是SHPT的主要治疗药物，但对重度SHPT患者往往无效，或因血钙磷水平控制欠佳难以给予药物治疗。对此类患者可给予手术或消融治疗。消融治疗作为一种微创手术，越来越多地应用于临床治疗SHPT，取得了许多新的进展。

Secondary hyperparathyroidism （SHPT） is the common complication in chronic kidney disease patients, especially in those with hemodialysis, which is associated with cardiovascular events and mortality. Active vitamin D and its analogues are classic treatment for SHPT, but some patients are resistant to active vitamin D, and ablation would be a choice for such cases. The purpose of this review is to provide current progress in ablation for SHPT.